Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors
NCT03074513 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 133
Last updated 2026-03-11
Summary
This phase II trial studies how well atezolizumab and bevacizumab work in treating patients with rare solid tumors. Immunotherapy with monoclonal antibodies, such as atezolizumab and bevacizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
Conditions
- Appendix Adenocarcinoma
- Human Papillomavirus-Related Anal Squamous Cell Carcinoma
- Human Papillomavirus-Related Cervical Squamous Cell Carcinoma
- Human Papillomavirus-Related Squamous Cell Carcinoma of the Penis
- Human Papillomavirus-Related Vulvar Squamous Cell Carcinoma
- Neuroendocrine Carcinoma
- Pancreatic Neuroendocrine Tumor
- Recurrent Merkel Cell Carcinoma
- Recurrent Nasopharynx Carcinoma
- Recurrent Peritoneal Malignant Mesothelioma
- Recurrent Pleural Malignant Mesothelioma
- Stage III Merkel Cell Carcinoma AJCC v7
- Stage III Nasopharyngeal Carcinoma AJCC v7
- Stage III Pleural Malignant Mesothelioma AJCC v7
- Stage IV Merkel Cell Carcinoma AJCC v7
- Stage IV Nasopharyngeal Carcinoma AJCC v7
- Stage IV Pleural Malignant Mesothelioma AJCC v7
- Stage IVA Nasopharyngeal Carcinoma AJCC v7
- Stage IVB Nasopharyngeal Carcinoma AJCC v7
- Stage IVC Nasopharyngeal Carcinoma AJCC v7
- Vaginal Squamous Cell Carcinoma, Not Otherwise Specified
Interventions
- DRUG
-
Given IV
- BIOLOGICAL
-
Given IV
- OTHER
-
Laboratory Biomarker Analysis
Correlative studies
- OTHER
-
Pharmacological Study
Correlative studies
Sponsors & Collaborators
-
National Cancer Institute (NCI)
collaborator NIH -
M.D. Anderson Cancer Center
lead OTHER
Principal Investigators
-
Kanwal P Raghav, MD · M.D. Anderson Cancer Center
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2017-03-03
- Primary Completion
- 2027-09-30
- Completion
- 2027-09-30
- FDA Drug
- Yes
Countries
- United States
Study Locations
More Related Trials
-
Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer
NCT05098210 ·Status: RECRUITING ·Phase: PHASE1
-
Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma
NCT04940299 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
VX15/2503 With or Without Ipilimumab and/or Nivolumab in Patients With Resectable Stage IIIB-D Melanoma
NCT03769155 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Vaccine Therapy in Treating Patients With Stage IIC-IV Melanoma
NCT00085189 ·Status: COMPLETED ·Phase: PHASE2
-
Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial Carcinoma
NCT03513952 ·Status: COMPLETED ·Phase: PHASE2
-
Monoclonal Antibody Therapy in Treating Patients With Relapsed or Refractory Solid Tumors
NCT00005061 ·Status: COMPLETED ·Phase: PHASE1
-
Monoclonal Antibody and Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Has Been Removed During Surgery
NCT00025181 ·Status: COMPLETED ·Phase: PHASE1
-
An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942)
NCT03897881 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
A Study of Atezolizumab in Advanced Solid Tumors
NCT02458638 ·Status: COMPLETED ·Phase: PHASE2
-
BEAT-meso: Bevacizumab and Atezolizumab in Malignant Pleural Mesothelioma
NCT03762018 ·Status: COMPLETED ·Phase: PHASE3
-
Laboratory-Treated T Cells and Ipilimumab in Treating Patients With Metastatic Melanoma
NCT00871481 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors
NCT05286801 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Nivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in Treating Patients With High Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma
NCT03220009 ·Status: WITHDRAWN ·Phase: PHASE2
-
A Study of VET3-TGI in Patients With Solid Tumors
NCT06444815 ·Status: RECRUITING ·Phase: PHASE1
-
Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck Cancer
NCT03809624 ·Status: TERMINATED ·Phase: PHASE1
-
Rituximab and Hyaluronidase Human in Patients With Advanced Melanoma Undergoing Nivolumab and Ipilimumab Therapy
NCT03719131 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Bevacizumab in Treating Patients With Angiosarcoma
NCT00288015 ·Status: COMPLETED ·Phase: PHASE2
-
Phase II Trial of Immunotherapy in Patients With Carcinomas Arising From the Renal Medulla
NCT05347212 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas
NCT02304458 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Peptide Vaccination for Patients at High Risk for Recurrent Melanoma
NCT00059475 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of the Safety and Pharmacology of MEGF0444A in Combination With Bevacizumab With or Without Paclitaxel in Patients With Locally Advanced or Metastatic Solid Tumors
NCT01075464 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of MNRP1685A in Combination With Bevacizumab With or Without Paclitaxel in Patients With Locally Advanced or Metastatic Solid Tumors
NCT00954642 ·Status: COMPLETED ·Phase: PHASE1
-
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
NCT03866382 ·Status: RECRUITING ·Phase: PHASE2
-
Chemotherapy With or Without Immunotherapy for Peritoneal Mesothelioma
NCT05001880 ·Status: RECRUITING ·Phase: PHASE2
-
Vaccine Therapy and Monoclonal Antibody Therapy in Treating Patients With Stage IV Melanoma
NCT00032045 ·Status: COMPLETED ·Phase: PHASE2